• No results found

[PDF] Top 20 <p>Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment</p>

Has 10000 "<p>Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment</p>" found on our website. Below are the top 20 most common "<p>Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment</p>".

&lt;p&gt;Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment&lt;/p&gt;

<p>Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment</p>

... for enasidenib was published by Stein et al in ...multinational clinical trial, conducted from September 2013 to April 2016, that assessed enasidenib in humans for the fi rst ...of enasidenib ... See full document

8

&lt;p&gt;MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)&lt;/p&gt;

<p>MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)</p>

... Abstract: Acute myeloid leukemia (AML) is a clonal heterogenous malignancy of the myeloid cells with a poor prognosis lending itself to novel treatment ...suggest clinical ... See full document

8

&lt;p&gt;Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy&lt;/p&gt;

<p>Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy</p>

... for enasidenib found that patients with IDH2-R140 mutations had a median 93% reduction in 2-HG levels (maximum 99%), while patients with IDH2-R172 had a median 28% reduction (maximum ... See full document

15

&lt;p&gt;Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date&lt;/p&gt;

<p>Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date</p>

... the clinical development of midostaurin has been ongoing for many ...had clinical activity, the duration of response was limited as a single agent, so combination approaches were prioritized over ... See full document

13

&lt;p&gt;Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection&lt;/p&gt;

<p>Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection</p>

... based on currently evaluable data is unclear and unfortu- nately no matter how we dissect and analyze the RATIFY data this is a topic on which we (or others) will not be able to make any de fi nitive conclusions or ... See full document

12

&lt;p&gt;Evaluating venetoclax and its potential in treatment-na&amp;iuml;ve acute myeloid leukemia&lt;/p&gt;

<p>Evaluating venetoclax and its potential in treatment-na&iuml;ve acute myeloid leukemia</p>

... with venetoclax, as well. Cyclin-dependent kinase 9 (CDK9) acts as a transcriptional regulator for MCL-1; inhibition therefore causes downregulation of its transcrip- tion and a reduction in concentration. 55 This ... See full document

17

&lt;p&gt;PIM3 Promotes the Proliferation and Migration of Acute Myeloid Leukemia Cells&lt;/p&gt;

<p>PIM3 Promotes the Proliferation and Migration of Acute Myeloid Leukemia Cells</p>

... in clinical or pre- clinical ...the treatment of FLT3- ITD-positive ...The development of an ef fi cient PIM targeting strategy may rely on a better understanding of the function of each PIM ... See full document

9

Papadaki, Christina
  

(2017):


	Detection of minimal residual disease in Acute Myeloid Leukemia with t(8;21) translocation.


Dissertation, LMU München: Medizinische Fakultät

Papadaki, Christina (2017): Detection of minimal residual disease in Acute Myeloid Leukemia with t(8;21) translocation. Dissertation, LMU München: Medizinische Fakultät

... AML is a disease with wide clinical and biological diversity. During the last decade much progress has been made in understanding the molecular and cytogenetic basis of acute leukemia. This ... See full document

82

Biological and clinical influences of &lt;em&gt;NPM1 &lt;/em&gt;in acute myeloid leukemia patients with &lt;em&gt;DNMT3A&lt;/em&gt; mutations

Biological and clinical influences of <em>NPM1 </em>in acute myeloid leukemia patients with <em>DNMT3A</em> mutations

... and clinical features with companion ...and clinical characteristics of these patients with DNMT3A mutations is important for estimating their event-free survival (EFS) and overall survival (OS) and likely ... See full document

9

&lt;p&gt;A personalized approach to acute myeloid leukemia therapy: current options&lt;/p&gt;

<p>A personalized approach to acute myeloid leukemia therapy: current options</p>

... of clinical trials on AML patients, it has been hardly used to stratify, due to extended turnaround times, which often delay the ...97–99 Clinical trials like the BEAT AML study aimed to inte- grate genomic ... See full document

13

A Morphological Study of Acute Myeloid Leukemia and Correlation With Clinical and Laboratory Findings, Including Results of Cytogenetic Analysis and Mutation Screening

A Morphological Study of Acute Myeloid Leukemia and Correlation With Clinical and Laboratory Findings, Including Results of Cytogenetic Analysis and Mutation Screening

... Several clinical trial groups proposed different risk group stratification schemes based on the cytogenetic and molecular profiles ...different treatment approaches were the major factors affecting the ... See full document

136

Case Report Hemophagocytic lymphohistiocytosis in patients with acute myeloid leukemia: a report of three cases and literature review

Case Report Hemophagocytic lymphohistiocytosis in patients with acute myeloid leukemia: a report of three cases and literature review

... of leukemia with HLH is relatively rare and has been seldom reported ...[3]. Clinical manifestations of HLH ...delayed treatment or even early death [5]. Here, this study reports the clinical ... See full document

5

&lt;p&gt;Molecular Targeting and Rational Chemotherapy in Acute Myeloid Leukemia&lt;/p&gt;

<p>Molecular Targeting and Rational Chemotherapy in Acute Myeloid Leukemia</p>

... consolidation treatment for patients with AML has no signi fi cant impact on survival parameters in comparison to intermediate-/low-dose (ID/LD) ...are treatment trials with cumulative HD cytarabine doses ... See full document

22

&lt;p&gt;T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia&lt;/p&gt;

<p>T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia</p>

... direct clinical evidence of antileukemia- speci fi c cytotoxic T lymphocytes (CTLs) originated from the relapse of chronic myeloid leukemia (CML) after donor lymphocyte infusion (DLI) treatment ... See full document

10

&lt;p&gt;Significance of CXCL12/CXCR4 Ligand/Receptor Axis in Various Aspects of Acute Myeloid Leukemia&lt;/p&gt;

<p>Significance of CXCL12/CXCR4 Ligand/Receptor Axis in Various Aspects of Acute Myeloid Leukemia</p>

... Abstract: Acute myeloid leukemia (AML) is de fi ned as an aggressive disorder which is described by accumulation of immature malignant cells into the bone ...between leukemia cells and bone ... See full document

11

&lt;p&gt;Quizartinib (AC220): a promising option for acute myeloid leukemia&lt;/p&gt;

<p>Quizartinib (AC220): a promising option for acute myeloid leukemia</p>

... Acute myeloid leukemia (AML) is a heterogeneous disease characterized by multiple genetic ...immunology, clinical features and ...the treatment of AML compared with the past. ... See full document

9

&lt;p&gt;Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain&lt;/p&gt;

<p>Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain</p>

... When comparing two potentially curative interven- tions, and in line with the recommendations of pharma- coeconomic guidelines, our study adopted a lifetime time horizon. The availability of long-term overall survival ... See full document

12

&lt;p&gt;Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis&lt;/p&gt;

<p>Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis</p>

... II clinical trials, which may be in the range of the relatively low con- fi ...using treatment protocols containing cladri- bine without the requirement of identical combination strategies and doses of the ... See full document

12

Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?

Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?

... some clinical cases, hepatotoxicity was also reported during administration of ...sorafenib treatment, we therefore conducted a meta-analysis based on 19 clinical trials, including acute ... See full document

11

The Philadelphia chromosome in leukemogenesis

The Philadelphia chromosome in leukemogenesis

... positive leukemia [8–10]. Leukemia stem cells and BCR- ABL kinase domain mutations may be the keys to solve these problems ...of acute myeloid leukemia (AML) [12, 13], acute ... See full document

15

Show all 10000 documents...